Organization Overview
Alternative names
autologous cd19/cd22 chimeric antigen receptor t-cells (2 trials)
brentuximab vedotin (adcetris) (1 trial)
Anemia (Phase 3)
Anemia, Aplastic (Phase 3)
beta-Thalassemia (Phase 3)
Communicable Diseases (Phase 3)
Deficiency Diseases (Phase 2)
Graft vs Host Disease (Phase 3)
Granuloma (Phase 2)
Granuloma, Plasma Cell (Phase 3)
Granulomatous Disease, Chronic (Phase 2)
Hematologic Diseases (Phase 3)
Hepatoblastoma (Phase 3)
Histiocytosis (Phase 2)
Histiocytosis, Langerhans-Cell (Phase 2)
Hodgkin Disease (Phase 2)
Immunologic Deficiency Syndromes (Phase 2)
Infections (Phase 3)
Leukemia (Phase 3)
Leukemia, Lymphoid (Phase 2)
Leukemia, Myeloid (Phase 3)
Leukemia, Myeloid, Acute (Phase 3)
Lymphoma (Phase 2)
Myelodysplastic Syndromes (Phase 3)
Nijmegen Breakage Syndrome (Phase 2)
Opportunistic Infections (Phase 3)
Pancytopenia (Phase 2)
Sprains and Strains (Phase 2)
Syndrome (Phase 2)
Thalassemia (Phase 3)
Thrombocytopenia (Phase 2)
Wiskott-Aldrich Syndrome (Phase 2)